STERIS plc (STE)

FairStock Score: 52/100 — MIXED

Key Financials

Strengths

• Recurring revenue model through infection prevention and sterilization services with high switching costs
• Strong free cash flow generation of $870.7M demonstrates underlying business quality
• Essential healthcare services with demographic tailwinds and regulatory protections
• Conservative balance sheet with 0.29 D/E ratio and Altman Z-Score of 4.58 indicating financial stability
• Q4 2025 net margin of 12.89% shows operational execution capability

Concerns

• Extreme valuation disconnect: $222 price vs $56.70 Graham Number represents 291% overvaluation with zero margin of safety
• Deteriorating financial quality with Piotroski F-Score of only 6/9 suggesting weakening fundamentals
• Anemic returns: 10.47% ROE and 6.61% ROCE barely exceed cost of capital, questioning capital allocation efficiency
• Expensive valuation multiples (P/E 30.69, EV/EBITDA 59.35x) leave no room for any business disappointment

AI Analysis

I'm looking at STERIS with considerable skepticism. Here's a business with genuine moat characteristics—infection prevention and sterilization services benefit from regulatory barriers, switching costs, and recurring revenue streams. The healthcare segment shows promise with 12.89% margins in Q4 2025, and $870.7M in free cash flow demonstrates operational substance. However, the valuation presents a troubling disconnect from intrinsic value. At $222, STERIS trades at a P/E of 30.69 with a Graham Number of just $56.70, implying a negative 291% margin of safety. This isn't margin of safety—it's a margin of folly. The EV/EBITDA of 59.35x is extraordinarily expensive for a business generating 10.47% ROE and 6.61% ROCE. These returns barely exceed the cost of capital. The Piotroski F-Score of 6/9 suggests deteriorating financial quality, while the FairStock Score of 45/100 confirms overvaluation. Yes, STERIS operates in attractive markets with demographic tailwinds and essential services. But I've learned that a wonderful business at a foolish price becomes a poor investment. The market has priced in perfection—sustained double-digit growth, margin expansion, and multiple expansion. Any disappointment will be punishing. I cannot justify paying nearly $4 of market value for every $1 of book value, nor can I ignore an enterprise value nearly 60 times EBITDA. Graham would call this speculation masquerading as investment. I'm passing.

Bull Case

STERIS operates in essential healthcare with structural growth drivers including aging populations, surgical procedure volume increases, and infection control spending. Strong free cash flow generation and conservative leverage enable increased shareholder returns, potentially validating premium valuations if management demonstrates sustained mid-to-high single-digit organic growth.

Bear Case

Multiple compression is inevitable when a company trading at 60x EBITDA with 10% ROE faces any macroeconomic headwind or market sentiment shift. Investors have priced in perfection; any misses on growth targets or margin guidance will trigger significant downside as premium valuations collapse toward intrinsic value.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer